Randomized, double-blind, placebo-controlled trial in 121 infants aged 4-5 months with eczema at two Japanese centers: stepwise introduction of heated whole-egg powder (from 6 months, low then higher dose) plus aggressive eczema treatment, versus placebo powder plus the same eczema treatment. At age 1 year, egg allergy (oral food challenge-confirmed) occurred in 8% of the egg-introduction group versus 38% of placebo — the largest effect size reported to date among egg-early-introduction trials, and (unlike the STAR trial) achieved with an escalating heated-egg protocol and close eczema management, without excess adverse reactions.
relevance_note: The most robust primary RCT evidence that early, controlled egg introduction actively prevents egg allergy in a high-risk population (infants with eczema) rather than merely being safe — central to the allergy/early-introduction thread’s benefit side.
Methodology
Randomised, double-blind, placebo-controlled trial (preregistered UMIN000008673) at two Japanese centres. 121 infants aged 4-5 months with eczema were randomised 1:1 (block size 4, stratified by institution and sex, allocation concealed, participants and physicians masked) to early egg introduction versus placebo. The egg group consumed 50 mg/day heated whole-egg powder from 6-9 months, then 250 mg/day until 12 months; both groups received aggressive eczema treatment maintained without exacerbation throughout. Primary outcome: proportion with hen’s-egg allergy confirmed by standardised, blinded open oral food challenge at 12 months, in all randomised participants who received the intervention. The trial was stopped early at a scheduled interim analysis of 100 participants.
Results
O-20 - Early stepwise heated-egg introduction cut confirmed egg allergy at 12 months to 8% vs 38% placebo in eczema infants (PETIT RCT)
Primary outcome of the PETIT trial. Egg group received 50 mg/day heated egg powder from 6-9 months then 250 mg/day to 12 months. The trial was terminated early at a scheduled interim analysis of 100 participants (egg allergy 4/47 [9%] egg vs 18/47 [38%] placebo; RR 0.222 [0.081-0.607]; p=0.0012); interim stopping typically inflates the point estimate. Largest reported effect size among egg early-introduction trials.
Link to originalMethodology
Randomised, double-blind, placebo-controlled trial (preregistered UMIN000008673) at two Japanese centres. 121 infants aged 4-5 months with eczema were randomised 1:1 (block size 4, stratified by institution and sex, allocation concealed, participants and physicians masked) to early egg introduction versus placebo. The egg group consumed 50 mg/day heated whole-egg powder from 6-9 months, then 250 mg/day until 12 months; both groups received aggressive eczema treatment maintained without exacerbation throughout. Primary outcome: proportion with hen’s-egg allergy confirmed by standardised, blinded open oral food challenge at 12 months, in all randomised participants who received the intervention. The trial was stopped early at a scheduled interim analysis of 100 participants.
Link to original
O-21 - Early egg introduction raised hospital admissions (10% vs 0%) though acute-reaction rates were similar between arms (PETIT)
Safety signal: the intervention was not free of acute allergic reactions — hospital admissions (for reactions to the egg powder) were significantly higher in the egg arm, even though the overall count of participants with acute events after powder intake was slightly lower in the egg arm than placebo.
Link to original
Interpretation
H-10 - Early stepwise egg introduction causally prevents egg allergy in high-risk infants
The causal, generalizable claim the trial’s measured effect supports: introducing (rather than delaying) heated egg induces oral tolerance and prevents allergy in the high-risk eczema population.
Link to original
A-4 - Identical eczema treatment in both arms isolates the causal effect of egg introduction, not eczema management
Validity verdict (step 6)
Link to original
approved,checked. Reconstruction: premises are that both arms received identical aggressive eczema treatment, the sole between-arm difference was heated-egg vs placebo powder, and randomization (block 4, stratified, concealed, double-blind) balanced baseline risk; conclusion is that the OFC-confirmed allergy difference isolates the causal effect of egg introduction rather than eczema/skin-barrier management. Traced step: this is standard RCT contrast logic — holding the co-intervention (eczema management, hence the transcutaneous-sensitization route) constant across arms means it cancels in the between-arm difference, and randomization removes systematic baseline imbalance, so the residual difference is attributable to the one factor that varied. The natural undercutting probe (the effect is confounded by differential skin-barrier care) is explicitly closed by the identical-treatment premise, and no alternative factor differs by arm, so no defeater survives. The one caveat the body raises — interim stopping likely inflates the point estimate — concerns effect magnitude (a strength/likelihood matter priced downstream), not the validity of the causal-isolation step, so it does not move the verdict. Author-blind: rests on the trial design, not the source. The intervention bundled two components: stepwise heated-egg introduction and aggressive eczema control. A skeptic could attribute the allergy prevention to improved skin-barrier/eczema management (the transcutaneous-sensitization route, in which allergen exposure through inflamed skin drives sensitization) rather than to oral tolerance induction. But the placebo arm received the same aggressive eczema treatment; the only between-arm difference was heated-egg versus placebo powder. Randomization (block size 4, stratified by site and sex, allocation concealed, double-blind) balanced baseline risk. Holding eczema management constant across arms, the difference in OFC-confirmed allergy (8% vs 38%) therefore isolates the causal contribution of oral egg introduction. The far-from-threshold p (0.0001) and large absolute effect make chance implausible, though early interim stopping means the point estimate likely overstates the true effect magnitude.